Research on Disease Control and Mental Health Status of Adolescent Asthma Patients

February 12, 2026 updated by: Kunling Shen, Beijing Children's Hospital

Background: Currently in China, adolescent asthma care is characterized by both undertreatment and overtreatment. Patients in this age group may exhibit negative emotions toward disease treatment and long-term control. Insufficient disease knowledge, irregular lifestyle habits, and negative attitudes toward the disease can all reduce medication adherence, affect disease control outcomes, and thereby increase the risk of severe chronic respiratory conditions and disease burden in adulthood.

Objectives: To assess disease control status in adolescent asthma patients, evaluate the psychological well-being of patients and their family members, and understand patients' self-management skills and readiness for transition to adulthood.

Procedures: Eligible participants will complete a series of assessment questionnaires through the Youran Huxi mobile application, including questionnaires on asthma control, physical activity, psychological health, self-management behaviors, and transition readiness. The study period is 12 months; the baseline assessment involves one-time completion of written questionnaires with no interim follow-up visits. The study does not intervene in clinical diagnosis or treatment decisions.

Study Overview

Status

Not yet recruiting

Conditions

Intervention / Treatment

Study Type

Observational

Enrollment (Estimated)

460

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Child
  • Adult

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Population

This study recruited children with asthma and their parents from the hospital outpatient clinic as research participants. The inclusion criteria were: meeting the GINA 2025 diagnostic criteria for asthma; children aged 12-18 years; and both parents and children provided informed consent and were able to complete the questionnaires. The exclusion criteria were: children with other respiratory diseases such as bronchiectasis, bronchiolitis, cystic fibrosis, or pneumonia; and those with other chronic systemic diseases including diabetes, kidney disease, lupus erythematosus, skin diseases, epilepsy, heart disease, or arthritis.

Description

Inclusion Criteria:

  • Meet the asthma diagnostic criteria of GINA 2025
  • Age 12 to 18 years old
  • The parents and the child patient agreed and filled out the questionnaire completely.

Exclusion Criteria:

  • Children with other respiratory diseases such as bronchiectasis, bronchiolitis, cystic fibrosis and pneumonia
  • Combined with chronic diseases of other systems

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Adolescent asthma patients
Adolescents diagnosed with asthma
Other: Eligible participants will complete a battery of assessment questionnaires
Data on demographic characteristics, asthma control status, anxiety and depression symptoms, self-management self-efficacy, and transition readiness were collected via standardized questionnaires

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
anxiety state
Time Frame: From the diagnosis of asthma to the end of this survey at 12month

Total scores on the Screen for Childhood Anxiety and Related Emotional Disorders (SCARED) ranging from 0 to 24 are considered within the non-clinical range, indicating minimal anxiety symptoms.

SCARED total scores of 25-41 indicate mild to moderate anxiety symptoms. Scores of 42 or above suggest moderate to severe anxiety symptoms, indicating probable anxiety disorder.
From the diagnosis of asthma to the end of this survey at 12month
depression state
Time Frame: From the diagnosis of asthma to the end of this survey at 12month

A score of 16 to 19 on the Child Depression Scale (CDI) indicates mild depressive symptoms, and attention should be paid to psychological state.

A score of 20 to 24 indicates moderate depressive symptoms. A score of 25 or above indicates severe depressive symptoms, suggesting the possible presence of depressive disorders.
From the diagnosis of asthma to the end of this survey at 12month

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
disease control level
Time Frame: From the 4 weeks prior to enrollment to the end of this survey at 12month

The Asthma Control Test (ACT) will be employed for assessment, with the following interpretation criteria:

A total score of 20-25 indicates well-controlled asthma; A score of 16-19 suggests poorly controlled asthma; A score of 5-15 reflects very poorly controlled asthma.
From the 4 weeks prior to enrollment to the end of this survey at 12month
Adolescent readiness for the transition period of asthma
Time Frame: From the diagnosis of asthma to the end of this survey at 12month

The STARx Transition Readiness Questionnaire (scale) is suitable for patients aged 12 to 22 and is filled out by adolescent patients.

There are a total of 6 dimensions, divided into drug management (4 items), doctor-patient communication (3 items), participation in medical visits (3 items), assumption of health responsibility (2 items), disease knowledge (3 items), and resource utilization (3 items), totaling 18 items.

It is divided into five levels from 1 to 5, each assigned a score of 1, 2, 3, 4, and 5 respectively. The transition period preparation score is the sum of the scores of each item.

The higher the score, the more thorough the transition period preparation and the better the self-care ability.
From the diagnosis of asthma to the end of this survey at 12month

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Beijing Children's Hospital

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

April 1, 2026

Primary Completion (Estimated)

October 1, 2027

Study Completion (Estimated)

December 1, 2027

Study Registration Dates

First Submitted

February 6, 2026

First Submitted That Met QC Criteria

February 12, 2026

First Posted (Actual)

February 17, 2026

Study Record Updates

Last Update Posted (Actual)

February 17, 2026

Last Update Submitted That Met QC Criteria

February 12, 2026

Last Verified

February 1, 2026

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • Adolescent Asthma 001

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Adolescent - Emotional Problem

Clinical Trials on Eligible participants will complete a battery of assessment questionnaires

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Trinidad & Tobago

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe